Bicara Therapeutics宣布1.5亿美元普通股及预付认股权证公开发行定价

美股速递
Feb 25

Bicara Therapeutics已正式确定其1.5亿美元普通股及预付认股权证的公开发行价格。此次融资将支持公司推进其肿瘤治疗产品管线的临床开发。市场密切关注此次发行对公司未来发展的影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10